IAM Patent 1000 2024 Ranks Cravath in Gold Tier and Recognizes Five Cravath Attorneys
June 13, 2024
The IAM Patent 1000 2024, which recognizes the firms and individuals “deemed outstanding in the pivotal area of patent law,” ranked Cravath in the top tier for New York across Litigation and Transactions. In addition, Cravath partners Keith R. Hummel, David J. Kappos, David R. Marriott, Sasha Rosenthal‑Larrea and Sharonmoyee Goswami were recognized for their “outstanding service” and representation of clients on litigation and transactional matters including Johnson & Johnson in its $16.6 billion acquisition of Abiomed; Abiomed in its victory before the U.S. Patent Trial and Appeal Board; and Truist Bank in patent infringement litigation brought by United Services Automobile Association.
Related Practices & Industries
People
- Photo
-
-
J.D., 1990, Georgetown University Law CenterOrder of the Coif, magna cum laude
-
B.A., 1987, University of Notre Dame
- New York
Education
Admitted In
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 1994, New York University School of Law
-
B.A., 1991, Brigham Young Universitymagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2010, Columbia Law SchoolHarlan Fiske Stone Scholar
-
A.B., 2007, Brown University
- New York
Education
Admitted In
- Photo
-
-
J.D., 2012, New York University School of LawOrder of the Coif, magna cum laude
-
B.S.E., 2009, Princeton University
- New York
Education
Admitted In
Related News
Deals & Cases
November 01, 2022
Johnson & Johnson’s $16.6 Billion Acquisition of Abiomed
On November 1, 2022, Johnson & Johnson and Abiomed, a leader in breakthrough heart, lung and kidney support technologies, announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. Abiomed shareholders will also receive a non-tradeable contingent value right (“CVR”) entitling the holder to receive up to $35 per share in cash if certain commercial and clinical milestones are achieved. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
January 31, 2023
Abiomed Secures Victory Before the U.S. Patent Trial and Appeal Board
In January, 2023, Cravath client Abiomed Inc. (“Abiomed”) secured a victory before the U.S. Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”).
